ES2365852T3 - Utilización de fragmentos del factor de crecimiento de fibroblastos. - Google Patents

Utilización de fragmentos del factor de crecimiento de fibroblastos. Download PDF

Info

Publication number
ES2365852T3
ES2365852T3 ES04797676T ES04797676T ES2365852T3 ES 2365852 T3 ES2365852 T3 ES 2365852T3 ES 04797676 T ES04797676 T ES 04797676T ES 04797676 T ES04797676 T ES 04797676T ES 2365852 T3 ES2365852 T3 ES 2365852T3
Authority
ES
Spain
Prior art keywords
source
mrna
protein
homo sapiens
fgf
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04797676T
Other languages
English (en)
Spanish (es)
Inventor
Jacques Bollekens
Salah-Dine Chibout
Jacky Vonderscher
François LEGAY
André Cordier
Ruben Papoian
Andreas Scherer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Pharma GmbH Austria
Novartis AG
Original Assignee
Novartis Pharma GmbH Austria
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma GmbH Austria, Novartis AG filed Critical Novartis Pharma GmbH Austria
Application granted granted Critical
Publication of ES2365852T3 publication Critical patent/ES2365852T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/40—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Primary Health Care (AREA)
  • Endocrinology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
ES04797676T 2003-11-07 2004-11-05 Utilización de fragmentos del factor de crecimiento de fibroblastos. Expired - Lifetime ES2365852T3 (es)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US51807303P 2003-11-07 2003-11-07
US518073P 2003-11-07
US57224704P 2004-05-18 2004-05-18
US572247P 2004-05-18
PCT/EP2004/012572 WO2005045044A2 (en) 2003-11-07 2004-11-05 Use of fibroblast growth factor fragments
US57847008A 2008-04-18 2008-04-18
US13/152,750 US20120028896A1 (en) 2003-11-07 2011-06-03 Use of fibroblast growth factor fragments

Publications (1)

Publication Number Publication Date
ES2365852T3 true ES2365852T3 (es) 2011-10-11

Family

ID=34576820

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04797676T Expired - Lifetime ES2365852T3 (es) 2003-11-07 2004-11-05 Utilización de fragmentos del factor de crecimiento de fibroblastos.

Country Status (7)

Country Link
US (3) US20090093398A1 (https=)
EP (1) EP1682665B1 (https=)
JP (1) JP5118851B2 (https=)
AT (1) ATE507296T1 (https=)
DE (1) DE602004032457D1 (https=)
ES (1) ES2365852T3 (https=)
WO (1) WO2005045044A2 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030220258A1 (en) * 2001-12-21 2003-11-27 Robbert Benner Treatment of ischemic events
US7358330B2 (en) * 2001-03-29 2008-04-15 Biotempt B.V. Immunoregulatory compositions
US7294704B2 (en) 2003-08-15 2007-11-13 Diadexus, Inc. Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
US20090227505A1 (en) * 2004-01-07 2009-09-10 Biotempt B.V. Methods and uses for protein breakdown products
JP2006347979A (ja) * 2005-06-17 2006-12-28 National Institute Of Advanced Industrial & Technology 創傷治療及び／又は創傷治癒促進のための薬剤
EP1864692A1 (en) * 2006-06-07 2007-12-12 Biotempt B.V. Use of peptides for the control of radiation injury
US11308462B2 (en) 2014-05-13 2022-04-19 Clear Token Inc Secure electronic payment
JP6232689B2 (ja) 2015-06-25 2017-11-22 株式会社国際電気通信基礎技術研究所 多器官連関システムを基盤とした予測装置、及び予測プログラム
CN114594268A (zh) 2016-03-29 2022-06-07 无限生物制药公司 用以预防或治疗肾脏疾病的活性组分的候选物质的筛选装置和筛选方法
EP3466446B1 (en) 2016-03-29 2023-12-27 Karydo Therapeutix, Inc. Pharmaceutical composition or food composition, and method for assessing effect of active ingredient in vivo
WO2021075535A1 (ja) * 2019-10-18 2021-04-22 国立大学法人滋賀医科大学 異常幹細胞を標的とする糖尿病治療
US20230382966A1 (en) * 2020-10-27 2023-11-30 Indiana University Research And Technology Corporation Novel klotho interaction site in the c-terminus of fgf23
CN114940990B (zh) * 2022-06-20 2023-03-14 北京市神经外科研究所 与颅内动脉瘤相关的基因突变位点及其应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001249125A1 (en) * 2000-03-08 2001-09-17 Chiron Corporation Human fgf-23 gene and gene expression products
US20030105302A1 (en) * 2000-03-08 2003-06-05 Nobuyuki Itoh Human FGF-23 gene and gene expression products
ES2340662T3 (es) * 2000-07-19 2010-06-08 Advanced Research And Technology Institute Factor de crecimiento de fibroblastos (fgf23) nuevo procedimiento para el uso.
AU2002214286A1 (en) * 2000-11-15 2002-05-27 Akiko Itai Method of profiling protein
JP2002223753A (ja) * 2001-01-30 2002-08-13 Hitachi Ltd 薬物応答解析用オリゴヌクレオチドアレイ
CA2443719A1 (en) * 2001-04-26 2002-11-07 Geneprot, Inc. Human fibroblast growth factor-related compositions
EP1491628A4 (en) * 2002-03-29 2006-10-18 Nat Inst Of Advanced Ind Scien NEW GALACTOSTRANSFERASES, PEPTIDES AND THESE CODING NUCLEIC ACID
JPWO2003091427A1 (ja) * 2002-04-24 2005-09-02 関西ティー・エル・オー株式会社 近位尿細管に発現する腎疾患関連遺伝子群

Also Published As

Publication number Publication date
JP5118851B2 (ja) 2013-01-16
US20090093398A1 (en) 2009-04-09
JP2007521799A (ja) 2007-08-09
EP1682665B1 (en) 2011-04-27
ATE507296T1 (de) 2011-05-15
WO2005045044A3 (en) 2005-11-10
US20130040882A1 (en) 2013-02-14
EP1682665A2 (en) 2006-07-26
HK1095160A1 (en) 2007-04-27
WO2005045044A2 (en) 2005-05-19
US20120028896A1 (en) 2012-02-02
DE602004032457D1 (de) 2011-06-09

Similar Documents

Publication Publication Date Title
US20120028896A1 (en) Use of fibroblast growth factor fragments
Pisarska et al. Forkhead l2 is expressed in the ovary and represses the promoter activity of the steroidogenic acute regulatory gene
Kratchmarova et al. A proteomic approach for identification of secreted proteins during the differentiation of 3T3-L1 preadipocytes to adipocytes
Yuan et al. Hexa‐D‐arginine treatment increases 7B2• PC2 activity in hyp‐mouse osteoblasts and rescues the HYP phenotype
Trošt et al. A microarray based identification of osteoporosis-related genes in primary culture of human osteoblasts
JP2002538841A (ja) ２７個のヒト分泌タンパク質
CHEN et al. The role of hypertension-related gene in aortic vascular smooth muscle cells from mice and rats
Lafont et al. Involvement of calcitonin and its receptor in the control of calcium‐regulating genes and calcium homeostasis in zebrafish (Danio rerio)
Honda et al. Regulation by 1α, 25‐dihydroxyvitamin D3 of expression of stanniocalcin messages in the rat kidney and ovary
Moin et al. Effectiveness of analog of Humanin in ameliorating streptozotocin-induced diabetic nephropathy in Sprague Dawley rats
US6368794B1 (en) Detection of altered expression of genes regulating cell proliferation
Fujinaka et al. Expression and localization of insulin‐like growth factor binding proteins in normal and proteinuric kidney glomeruli
JP2003514543A (ja) ２３個のヒト分泌タンパク質
EP2619330B1 (en) Method for identifying compounds to increase the expression or activity of aspartyl aminopeptidase
US20070099828A1 (en) Biomarkers for the efficacy of calcitonin and parathyroid hormone treatment
HK1095160B (en) Use of fibroblast growth factor fragments
EP1781817B1 (en) Method of screening for a carnitine transporter agonist or antagonist and its uses
JP2003520030A (ja) ２８個のヒト分泌タンパク質
Li et al. Effect of aging on the expression of adrenomedullin and its receptor component proteins in the male reproductive system of the rat
Nelson et al. Tumor expression studies indicate that HEM-1 is unlikely to be the active factor in oncogenic osteomalacia
US20030152963A1 (en) Human chromosome 15 and 16 bardet-biedl syndrome polynucleotides and polypeptides and methods of use
Chen et al. Total Flavonoids of Epimedium improve pulmonary vascular remodeling in pulmonary hypertension: network pharmacological analysis and experimental verification
EP2742947A1 (en) Bilirubin excretion enhancer
KR20070094785A (ko) 암, 특히 직장결장암 치료에서의 표적으로서의포스포리파제 ａ2의 확인 및 이의 작용 메카니즘
JP2002539847A (ja) ４９個のヒト分泌タンパク質